Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Khiron Life Sciences Corp KHRWF


Primary Symbol: V.KHRN.H Alternate Symbol(s):  V.KHRN.WT.H | KHRNF

Khiron Life Sciences Corp. is a Canada-based medical cannabis company with core operations in Latin America. The Company has its wholly owned medical health clinics and telemedicine platforms. The Company has two product lines: Medical Cannabis Products and Health Services. It sells branded medical cannabis products to patients with medical conditions. Under the Medical Cannabis Products line, the Company is focused on product sales in Latin America. The Company operates its own network of health centers (operating under the Zerenia brand) and Zerenia satellite clinics offering a suite of health, medical and surgical services, in alignment with both insurance company partners and private practice. Its subsidiaries include Khiron Life Sciences Corp. (Canada), Khiron Colombia S.A.S., Zerenia S.A.S., NettaGrowth International Inc., and others.


TSXV:KHRN.H - Post by User

Comment by Benedictuson Feb 19, 2021 11:32pm
221 Views
Post# 32617479

RE:RE:RE:RE:Let's hire a PR company to help get this moving

RE:RE:RE:RE:Let's hire a PR company to help get this moving

Exactly Handy.

My take: The company is an early mover in the B2C medicinal cannabis market. It's going to take patience. They are not operating in the free for all wild Wild West massive US market. Khiron is pursuing the less sexy medicinal side of this business where regulatory frameworks, bureaucratic hurdles and systemic resistance to the benefits of medicinal cannabis as a valid substitute to old school pharma approaches are all acting as a heavy drag on market entry and start up, speed of growth, script issuance and revenue build. Brazil, Germany and the UK are all definitely in this category. Columbia and Peru are growing nicely but revenue per patient is far lower than developed countries and so far the customer base is still small, so it is going to take time to have a meaningful impact on revenues and the sizable cash burn. When the stock traded at $4 it was valued near $500M market cap. If a mania retakes the sector based on US decriminalization and Mexico legalization it's possible this stock revisits such crazy valuations trading on thin air but to trade at such a market cap on real fundamentals is going to take a huge amount of proof of concept and for now there are way too many blanks to fill in on market penetration and growth trajectory, competitive advantages, etc. all imo. 

<< Previous
Bullboard Posts
Next >>